Quoting the release
PYC Therapeutics has completed a key translational milestone for its RNA platform by determining safe and well tolerated doses of its co-lead drug candidate in Non-Human Primates (monkeys)The results represent a major step towards first in-human clinical studies for thisprogram - the first potential therapy for patients with Retinitis Pigmentosa type 11 that addresses the underlying cause of the disease
pretty happy with that - now what will Mr market think of this?
Ann: Successful Completion of Key Translational Milestone, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.36 |
Change
0.005(0.37%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.40 | $1.36 | $211.9K | 152.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4103 | $1.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 2028 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |